Screening and Management of Comorbidities in Vitiligo

Autoimmune Comorbidities

Approximately 34 % of adults with vitiligo have autoimmune thyroid disease, making it the most common comorbidity to identify. 1
Familial clustering of vitiligo is observed in about 18 % of cases, supporting its autoimmune basis. 1, 2

Thyroid function testing (serum TSH ± free T4) should be performed in every patient at the time of vitiligo diagnosis. 1, 3, 4
Measurement of thyroid peroxidase antibodies is recommended alongside TSH at baseline to detect subclinical autoimmune thyroiditis. 1
A mandatory baseline screening algorithm for newly diagnosed vitiligo includes thyroid function tests and thyroid peroxidase antibody testing. 4
Additional laboratory investigations (complete blood count, vitamin B12, antinuclear antibodies, vitamin D, fasting glucose) may be ordered when clinical suspicion for other autoimmune or metabolic disorders exists. 4

Vitiligo markedly reduces health‑related quality of life, with psychological comorbidities occurring more frequently than in the general population. 3
Depression is present in roughly 10.8 % of vitiligo patients compared with 9.5 % in the general population. 3
Sleep disorders or insomnia affect about 5.9 % of vitiligo patients versus 4.4 % in the general population. 3
Social anxiety and low self‑esteem are especially common among women and individuals with darker skin types. 2, 3
A formal quality‑of‑life assessment should be completed at the initial dermatology consultation. 3

Under‑recognition of disease impact in lighter‑skinned individuals should be avoided; autoimmune associations remain equally important across skin types. 1, 4

The British Journal of Dermatology guidelines describe vitiligo as an acquired chronic depigmentation disorder characterized by progressive loss of functioning epidermal melanocytes, presenting as white patches that do not fluoresce under Wood's lamp examination 5, 6
Progressive depigmentation patches over time indicate the chronic, stepwise nature of melanocyte destruction, which is a characteristic feature of vitiligo 6, 7
No fluorescence on Wood's lamp is characteristic of vitiligo, as Wood's light delineates areas of complete pigment loss without enhancement 5, 8
The absence of surface changes in vitiligo skin distinguishes it from inflammatory or scaly conditions 6, 7

Autoimmune-mediated melanocyte destruction is the predominant mechanism, where immune activation leads to progressive loss of functioning epidermal and hair follicle melanocytes 9
Approximately 34% of adults with vitiligo have autoimmune thyroid disease, reflecting the strong autoimmune connection 6, 10

The British Journal of Dermatology guidelines recommend screening for thyroid function immediately in all adults with vitiligo, given the 34% prevalence of autoimmune thyroid disease 6, 7, 10
Failing to screen for thyroid disease is a critical error, as this represents a treatable comorbidity present in one-third of vitiligo patients 9, 10
The diagnosis of vitiligo can be made confidently in primary care, and Wood's light examination confirms complete depigmentation and helps assess disease extent 5, 8